雷贝拉唑、莫沙必利及麦滋林联合治疗反流性食管炎35例

Clinical Observation on Treatment of Reflux Esophagitis with Rabeprazole,Mosapride and Marzulene-s

目的观察雷贝拉唑、莫沙必利及麦滋林联合治疗反流性食管炎的临床疗效。方法将91例经胃镜确诊的反流性食管炎患者随机分为3组,治疗组35例给予雷贝拉唑10mg,1次/d,对照Ⅰ组28例给予奥美拉唑20mg,1次/d,对照Ⅱ组28例给予法莫替丁20mg,2次/d,3组均联用莫沙必利5mg,1次/d及麦滋林0.67g,3次/d,疗程8周。结果治疗组总有效率为97.14%,一日缓解率为83.25%,明显优于2个对照组,且不良反应少;症状平均消失天数与对照组亦有明显差异。结论雷贝拉唑、莫沙必利及麦滋林联合治疗反流性食管炎能迅速缓解症状,且安全可靠。

Objective To compare the efficacy of rabeprazole, mosapride and marzulene-s in the treatment of reflux esophagitis （RE）. Methods Ninety- one patients with endoscopically confirmed RE were randomized to three groups respectively. The treatment group （35 cases） was given rabeprazole 10 rag, once daily, the control group Ⅰ （28 cases） ,was given omeprazole 20 rag, once daily and the control group Ⅱ （28 cases） was given fammotidine 20 mg, twice daily. All patients were received mosaprlde 5 mg, once daily and marzulene-s 0. 67 g, t. i. d.,for 8 weeks. Results The total effective rate and daily remission rate of the treatment group were 97. 1% and 83.25% cespectively with less adverse reactions, and superior to the two control groups. There was significant difference on the average days of symptom disappearing between the treatment and control groups. Conclusion Combined rabeprazole, mosapride and marzulene-s for the treatment of reflux esophagitis can alleviate the symptoms with safety and reliability.